Health ❯ Chronic Diseases ❯ Respiratory Diseases

COPD

Patient Experiences Smoking-Related Illnesses Clinical Trials Impact of Smoking Health Risks of Smoking Disease Risk Factors Health Risks Heart Failure Cancer

8 ARTICLES

9mo ago

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

The pact underscores Chinese biotech’s rapid rise in global licensing, with Hengrui leading Phase I trials for the COPD asset before GSK’s later-stage development.